[go: up one dir, main page]

CL2018001776A1 - Agonista triple de receptores de glucagón/glp-1/gip - Google Patents

Agonista triple de receptores de glucagón/glp-1/gip

Info

Publication number
CL2018001776A1
CL2018001776A1 CL2018001776A CL2018001776A CL2018001776A1 CL 2018001776 A1 CL2018001776 A1 CL 2018001776A1 CL 2018001776 A CL2018001776 A CL 2018001776A CL 2018001776 A CL2018001776 A CL 2018001776A CL 2018001776 A1 CL2018001776 A1 CL 2018001776A1
Authority
CL
Chile
Prior art keywords
gip
glp
receptor agonist
glucagon receptor
triple
Prior art date
Application number
CL2018001776A
Other languages
English (en)
Inventor
Euh Lim Oh
Jong Suk Lee
Young Jin Park
Chang Ki Lim
Sung Youb Jung
Se Chang Kwon
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of CL2018001776A1 publication Critical patent/CL2018001776A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UN AGONISTA TRIPLE QUE TIENE ACTIVIDADES PARA TODOS LOS RECEPTORES DE GLUCAGÓN, GLP-1 Y GIP Y USOS DE LOS MISMOS.
CL2018001776A 2015-12-31 2018-06-28 Agonista triple de receptores de glucagón/glp-1/gip CL2018001776A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150191082 2015-12-31
KR20160163737 2016-12-02

Publications (1)

Publication Number Publication Date
CL2018001776A1 true CL2018001776A1 (es) 2018-08-10

Family

ID=59225193

Family Applications (6)

Application Number Title Priority Date Filing Date
CL2018001776A CL2018001776A1 (es) 2015-12-31 2018-06-28 Agonista triple de receptores de glucagón/glp-1/gip
CL2018001795A CL2018001795A1 (es) 2015-12-31 2018-06-29 Conjugado persistente de triple activador que activa el receptor de glucagón, glp-1 u gip
CL2020002034A CL2020002034A1 (es) 2015-12-31 2020-08-05 Agonista triple de receptores de glucagón/glp-1/gip. (divisional solicitud 201801776)
CL2020002033A CL2020002033A1 (es) 2015-12-31 2020-08-05 Conjugado persistente de triple activador que activa el receptor de glucagón, glp-1 u gip. (divisional solicitud 201801795)
CL2022000558A CL2022000558A1 (es) 2015-12-31 2022-03-07 Conjugado persistente de triple activador que activa el receptor de glucagón, glp-1 u gip (divisional 2 solicitud 202002033)
CL2022000557A CL2022000557A1 (es) 2015-12-31 2022-03-07 Agonista triple de receptores de glucagón/glp-1/gip (divisional 2 solicitud 202002034)

Family Applications After (5)

Application Number Title Priority Date Filing Date
CL2018001795A CL2018001795A1 (es) 2015-12-31 2018-06-29 Conjugado persistente de triple activador que activa el receptor de glucagón, glp-1 u gip
CL2020002034A CL2020002034A1 (es) 2015-12-31 2020-08-05 Agonista triple de receptores de glucagón/glp-1/gip. (divisional solicitud 201801776)
CL2020002033A CL2020002033A1 (es) 2015-12-31 2020-08-05 Conjugado persistente de triple activador que activa el receptor de glucagón, glp-1 u gip. (divisional solicitud 201801795)
CL2022000558A CL2022000558A1 (es) 2015-12-31 2022-03-07 Conjugado persistente de triple activador que activa el receptor de glucagón, glp-1 u gip (divisional 2 solicitud 202002033)
CL2022000557A CL2022000557A1 (es) 2015-12-31 2022-03-07 Agonista triple de receptores de glucagón/glp-1/gip (divisional 2 solicitud 202002034)

Country Status (32)

Country Link
US (6) US10400020B2 (es)
EP (3) EP3398961B1 (es)
JP (5) JP6712323B2 (es)
KR (8) KR20170080521A (es)
CN (6) CN108699125B (es)
AU (4) AU2016382394B2 (es)
BR (2) BR112018013530A2 (es)
CA (2) CA3010265C (es)
CL (6) CL2018001776A1 (es)
CO (2) CO2018006986A2 (es)
CR (2) CR20180381A (es)
DK (1) DK3398961T3 (es)
DO (2) DOP2018000157A (es)
EA (2) EA038544B1 (es)
EC (2) ECSP18053055A (es)
ES (1) ES2925098T3 (es)
HK (1) HK1258177A1 (es)
HR (1) HRP20220995T1 (es)
HU (1) HUE059737T2 (es)
IL (2) IL260310B2 (es)
MX (2) MX2018008027A (es)
PE (2) PE20250556A1 (es)
PH (2) PH12018501411B1 (es)
PL (1) PL3398961T3 (es)
PT (1) PT3398961T (es)
RS (1) RS63541B1 (es)
SA (2) SA518391891B1 (es)
SG (2) SG11201805573RA (es)
TN (2) TN2018000228A1 (es)
TW (4) TWI731015B (es)
WO (2) WO2017116205A1 (es)
ZA (2) ZA201804997B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
UA124182C2 (uk) * 2014-03-31 2021-08-04 Ханмі Фарм. Ко., Лтд. Спосіб покращення розчинності фізіологічно активного білка або пептиду
TW201639878A (zh) 2014-12-30 2016-11-16 韓美藥品股份有限公司 具有改善之安定性的升糖素衍生物
HUE066226T2 (hu) 2015-06-30 2024-07-28 Hanmi Pharmaceutical Co Ltd Glükagon származék és annak hosszú hatású konjugátumát tartalmazó készítmény
RS63541B1 (sr) * 2015-12-31 2022-09-30 Hanmi Pharm Ind Co Ltd Trojni aktivator koji aktivira glukagonski, glp-1 i gip receptor
AU2017289014B2 (en) 2016-06-29 2019-12-05 Hanmi Pharm. Co., Ltd. Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
US20200230250A1 (en) 2017-02-03 2020-07-23 Hanmi Pharm. Co., Ltd. Long-acting conjugate of a physiologically active material and use thereof
WO2018147641A1 (ko) 2017-02-07 2018-08-16 한미약품 주식회사 비펩티드성 중합체 링커 화합물, 그 링커 화합물을 포함하는 결합체, 및 이들의 제조방법
PE20191716A1 (es) 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
TWI767095B (zh) 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
TWI744579B (zh) 2017-12-21 2021-11-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
CN109239346B (zh) * 2018-10-31 2019-10-11 中国药科大学 一组代谢标志物在代谢综合征早期诊断方面的应用
WO2020130749A1 (ko) 2018-12-21 2020-06-25 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 및 인슐린을 포함하는 약학 조성물
EP3939990A4 (en) * 2019-02-15 2023-05-24 Hanmi Fine Chemical Co., Ltd. NOVEL INTERMEDIATE FOR BIOLOGICALLY ACTIVE POLYPEPTIDE AND PROCESS FOR THE PRODUCTION THEREOF
WO2020214012A1 (ko) * 2019-04-19 2020-10-22 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 고지혈증 예방 또는 치료용 약학적 조성물 및 예방 또는 치료 방법
WO2020214013A1 (ko) * 2019-04-19 2020-10-22 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 고지혈증에 대한 치료적 용도
CN111944055B (zh) * 2019-05-16 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
WO2020263063A1 (ko) * 2019-06-28 2020-12-30 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 간 질환에 대한 치료적 용도
PE20221049A1 (es) 2019-08-19 2022-06-30 Lilly Co Eli Metodos para preparar analogos de incretina
WO2021066600A1 (ko) * 2019-10-04 2021-04-08 한미약품 주식회사 글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도
MX2022005661A (es) 2019-11-11 2022-09-07 Boehringer Ingelheim Int Agonistas del receptor npy2.
AR120714A1 (es) 2019-12-18 2022-03-09 Lilly Co Eli Análogos de incretina y sus usos
CN111040022B (zh) * 2019-12-23 2021-12-14 万新医药科技(苏州)有限公司 针对胰高血糖素样肽-1受体、胰高血糖素受体、以及抑胃肽受体的三重激动剂
CN113597434B (zh) 2019-12-31 2022-07-01 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
WO2021145552A1 (ko) * 2020-01-13 2021-07-22 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체의 폐질환의 치료 용도
MA58498B1 (fr) 2020-02-07 2024-08-30 Gasherbrum Bio, Inc. Agonistes hétérocycliques de glp-1
TW202203963A (zh) * 2020-04-20 2022-02-01 南韓商韓美藥品股份有限公司 用於預防或治療高血脂症之包含三重升糖素／ｇｌｐ－１／ｇｉｐ受體促效劑或其接合物之組成物及其使用方法
KR20210144608A (ko) * 2020-05-22 2021-11-30 한미약품 주식회사 액상 제제
US20230285583A1 (en) * 2020-05-22 2023-09-14 Hanmi Pharm. Co., Ltd. Liquid formulation of long-acting conjugate of glucagon, glp-1, and gip trigonal agonist
EP4183419A4 (en) 2020-07-17 2025-04-02 Hanmi Pharm. Co., Ltd. THERAPEUTIC USE OF A COMBINATION WITH A LONG-ACTING TRIPLE AGONIST CONJUGATE OR TRIPLE AGONIST
IL300155A (en) 2020-08-06 2023-03-01 Gasherbrum Bio Inc Heterocyclic glp-1 agonists
AU2021322137A1 (en) 2020-08-07 2023-01-19 Boehringer Ingelheim International Gmbh Soluble NPY2 receptor agonists
TW202220700A (zh) * 2020-08-14 2022-06-01 南韓商韓美藥品股份有限公司 包含三重升糖素／ｇｌｐ－１／ｇｉｐ受體促效劑的長效接合物的醫藥組成物
WO2022035302A1 (ko) 2020-08-14 2022-02-17 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 혈압 강하용 약학 조성물
US20230355720A1 (en) 2020-09-25 2023-11-09 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for preventing or treating bone diseases, comprising triple agonist or conjugate thereof having activity with respect to all of glucagon, glp-1 and glp receptors
JP2023543036A (ja) * 2020-09-25 2023-10-12 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体またはその結合体の神経退行性疾患の治療用途
KR20220041766A (ko) 2020-09-25 2022-04-01 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체의 다발성 경화증의 치료 용도
WO2022068920A1 (en) 2020-09-30 2022-04-07 Beijing Ql Biopharmaceutical Co., Ltd. Polypeptide conjugates and methods of uses
EP4230218A4 (en) * 2020-10-16 2024-11-20 Hanmi Pharm. Co., Ltd. Pharmaceutical composition comprising glucagon/glp-1/gip triple agonist or long-acting conjugate thereof for preventing or treating vasculitis
TW202233226A (zh) * 2020-10-16 2022-09-01 南韓商韓美藥品股份有限公司 用於治療呼吸感染後遺症的三重升糖素／ｇｌｐ－１／ｇｉｐ受體促效劑
WO2022080989A1 (ko) * 2020-10-16 2022-04-21 한미약품 주식회사 글루카곤/glp-1/gip 삼중작용제 또는 이의 지속형 결합체를 포함하는 루푸스-관련 질환의 예방 또는 치료용 약학적 조성물
US20230381331A1 (en) * 2020-10-16 2023-11-30 Hanmi Pharm. Co., Ltd. Gip derivative, long-acting conjugate thereof, and pharmaceutical composition comprising same
CN116635055A (zh) * 2020-10-16 2023-08-22 韩美药品株式会社 包括gip衍生物或其长效缀合物的用于预防或治疗狼疮相关疾病的药物组合物
WO2022090447A1 (en) 2020-10-30 2022-05-05 Novo Nordisk A/S Glp-1, gip and glucagon receptor triple agonists
EP4257597A4 (en) * 2020-12-02 2025-04-02 Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. LACTAM-MODIFIED POLYPEPTIDE COMPOUNDS
KR20220092442A (ko) * 2020-12-24 2022-07-01 한미약품 주식회사 신규한 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중활성체 및 이의 용도
KR102691149B1 (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
WO2022164222A2 (ko) * 2021-01-29 2022-08-04 한미약품 주식회사 Gip 유도체 또는 이의 지속형 결합체를 포함하는 폐질환의 예방 또는 치료용 약학적 조성물
KR20240013798A (ko) 2021-05-26 2024-01-30 더 유나이티드 바이오-테크놀로지 (헝친) 컴퍼니 리미티드 다중 작용제 및 이의 사용
KR20230004135A (ko) * 2021-06-30 2023-01-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도
WO2023005841A1 (zh) * 2021-07-30 2023-02-02 南京明德新药研发有限公司 含内酰胺桥的多肽化合物
MX2024003236A (es) 2021-09-15 2024-06-19 Viking Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos.
KR20230095665A (ko) * 2021-12-22 2023-06-29 한미약품 주식회사 간 표적 약물 및 이의 용도
WO2023169456A1 (en) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Heterocyclic glp-1 agonists
US20250206757A1 (en) 2022-03-21 2025-06-26 Gasherbrum Bio, Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
CA3252113A1 (en) 2022-03-30 2023-10-05 Beijing Ql Biopharmaceutical Co., Ltd. Liquid pharmaceutical compositions of polypeptide conjugates and their methods of use
US20250250269A1 (en) 2022-04-14 2025-08-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
US20250296960A1 (en) * 2022-05-27 2025-09-25 D&D Pharmatech Inc. Peptide compositions and methods of use thereof
CN120530127A (zh) 2022-12-23 2025-08-22 韩美药品株式会社 新型三重glp-1/gip/胰高血糖素受体激动剂及包括其的用于预防或治疗肥胖症的药物组合物
IL322205A (en) 2023-01-31 2025-09-01 Lilly Co Eli GIP/GLP1/GCG trireceptor agonists and their uses
AU2024284396A1 (en) 2023-06-09 2026-01-08 Sun Pharmaceutical Industries Limited Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists
KR20250177375A (ko) * 2024-06-13 2025-12-23 한미약품 주식회사 Glp-1, gip, 및 글루카곤 수용체 모두에 활성을 갖는 삼중 활성체 및 이를 포함하는 지질 대사 질환 예방 또는 치료용 약학적 조성물
KR20250177377A (ko) * 2024-06-13 2025-12-23 한미약품 주식회사 Glp-1, gip, 및 글루카곤 수용체 모두에 활성을 갖는 삼중 활성체 및 이를 포함하는 당뇨 예방 또는 치료용 약학적 조성물
CN120189527A (zh) * 2025-05-27 2025-06-24 南方医科大学第三附属医院（广东省骨科研究院） 一种多肽与抗体Fc片段的偶联物、药物组合物及其用途

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5476304A (en) 1977-11-29 1979-06-18 Tokyo Printing Ink Mfg Co Ltd Ink
US5408037A (en) 1991-01-17 1995-04-18 Zymogenetics, Inc. Methods for detecting glucagon antagonists
GB9423277D0 (en) 1994-11-18 1995-01-11 Univ Nottingham Pulsed laser deposition of coatings
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP0904107B1 (en) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
PT1143989E (pt) * 1999-01-14 2007-03-30 Amylin Pharmaceuticals Inc Exendinas para supressão de glucagon
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
ATE346093T1 (de) * 2000-06-16 2006-12-15 Lilly Co Eli Analoge des glucagon ähnlichen peptid-1
EP1411968B1 (en) * 2001-07-31 2008-09-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Glp-1 exendin-4 peptide analogs and uses thereof
ES2390270T3 (es) * 2003-03-19 2012-11-08 Eli Lilly And Company Compuestos de GLP-1 unidos a polietilenglicol
TW200522976A (en) * 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
MXPA05007210A (es) 2003-11-13 2006-02-10 Hanmi Pharm Ind Co Ltd Complejo de proteina que usa un fragmento de inmunoglobulina y metodo para la preparacion del mismo.
CA2648936C (en) * 2006-04-20 2013-07-09 Amgen Inc. Glp-1 compounds
WO2007124045A2 (en) * 2006-04-20 2007-11-01 Ampla Pharmaceuticals, Inc. Piperidine and piperazine compounds for use in the treatment of obesity, eating disorders and sexual dysfunction by potentiation of mc4 receptor activity
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
CA2674354A1 (en) 2007-01-05 2008-07-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
GEP20135944B (en) 2007-02-15 2013-10-25 Indiana Unversity Research And Tech Corporation Glucagon/glp-1 receptor co-agonists
ATE520714T1 (de) 2007-06-15 2011-09-15 Zealand Pharma As Glucagonanaloga
AU2008264750C1 (en) 2007-06-19 2013-01-10 Glytech, Inc. GLP-1 peptide having sugar chain attached thereto
JP5476304B2 (ja) 2007-09-05 2014-04-23 ノボ・ノルデイスク・エー／エス グルカゴン様ペプチド−１誘導体及びそれらの医薬用途
CA2713348C (en) 2008-01-30 2018-10-09 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
TWI474832B (zh) * 2008-06-17 2015-03-01 Univ Indiana Res & Tech Corp 胰高血糖素／ｇｌｐ-１受體共同激動劑
EP2307037A4 (en) 2008-06-17 2011-08-03 Univ Indiana Res & Tech Corp GLUCAGON ANALOGUE WITH IMPROVED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL PH BUFFERS
CN102105159B (zh) 2008-06-17 2015-07-08 印第安纳大学研究及科技有限公司 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
RU2012101274A (ru) 2009-06-16 2013-07-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Соединения глюкагона, активные в отношении рецептора gip
CN104961822A (zh) 2009-07-13 2015-10-07 西兰制药公司 酰化胰高血糖素类似物
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
EA026384B1 (ru) 2010-01-20 2017-04-28 Зилэнд Фарма А/С Лечение заболеваний сердца
MX2012008603A (es) * 2010-01-27 2013-01-25 Univ Indiana Res & Tech Corp Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
JP5812627B2 (ja) * 2010-03-10 2015-11-17 公益財団法人相模中央化学研究所 改良Ｆｃ受容体およびその製造方法
US20130035285A1 (en) 2010-03-26 2013-02-07 Novo Nordisk A/S Novel glucagon analogues
JP6050746B2 (ja) 2010-05-13 2016-12-21 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
CN103458920B (zh) 2010-12-22 2016-07-06 印第安那大学科技研究公司 表现出gip受体活性的胰高血糖素类似物
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
KR20230023059A (ko) 2011-05-18 2023-02-16 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 제약
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
EP2718318B1 (en) 2011-06-10 2018-07-25 Hanmi Science Co., Ltd. Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
UA114709C2 (uk) 2011-06-17 2017-07-25 Ханмі Сайенс Ко., Лтд. Кон'югат, що містить похідну оксинтомодуліну, fc-ділянку імуноглобуліну та непептидильний полімер, та його застосування
SI2723367T1 (sl) * 2011-06-22 2017-08-31 Indiana University Research And Technology Corporation Koagonisti receptorja glukanona/GLP-1
KR20140043793A (ko) * 2011-06-22 2014-04-10 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/glp-1 수용체 공동-작용물질
US9944687B2 (en) 2011-07-04 2018-04-17 Imperial Innovations Limited Compounds and their effects on feeding behaviour
MX2014003579A (es) 2011-11-17 2015-04-10 Univ Indiana Res & Tech Corp Peptidos de la superfamilia de glucagon que presentan actividad del receptor de glucocorticoide.
US9745359B2 (en) 2012-05-18 2017-08-29 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
CN104583232B (zh) * 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 展现gip受体活性的胰高血糖素类似物
US20140051834A1 (en) * 2012-06-21 2014-02-20 Hoffmann-La Roche, Inc. Incretin Receptor Ligand Polypeptide Fc-Region Fusion Polypeptides And Conjugates With Altered Fc-Effector Function
SI2864350T1 (en) * 2012-06-21 2018-08-31 Indiana University Research And Technology Corporation GLUCAGON ANALOGUE ANALOGUE WITH ACTIVITY OF GIP RECEPTOR
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
WO2014049610A2 (en) * 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
SG10201602801YA (en) 2012-11-06 2016-05-30 Hanmi Pharm Ind Co Ltd Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
KR102365582B1 (ko) 2012-11-20 2022-02-18 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 약제
EP4047023A1 (en) * 2012-11-20 2022-08-24 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
SI2934568T1 (en) * 2012-12-21 2018-03-30 Sanofi Dual GLP1 / GIP or trigonal agonists GLP1 / GIP / glucagon
WO2014152460A2 (en) * 2013-03-15 2014-09-25 Indiana University Research And Technology Corporation Prodrugs with prolonged action
WO2014170496A1 (en) 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
US20160185837A1 (en) 2013-08-16 2016-06-30 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
CN106456589B (zh) 2013-12-18 2020-07-07 斯克利普斯研究所 修饰的治疗剂、订合的肽脂质缀合物及其组合物
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
JP6657230B2 (ja) * 2014-09-24 2020-03-04 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション インクレチン−インスリンコンジュゲート
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
TW201639878A (zh) 2014-12-30 2016-11-16 韓美藥品股份有限公司 具有改善之安定性的升糖素衍生物
HUE066226T2 (hu) 2015-06-30 2024-07-28 Hanmi Pharmaceutical Co Ltd Glükagon származék és annak hosszú hatású konjugátumát tartalmazó készítmény
TW201718629A (zh) 2015-09-25 2017-06-01 韓美藥品股份有限公司 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物
US20180360973A1 (en) 2015-12-02 2018-12-20 Hanmi Pharm. Co., Ltd. Protein conjugate using a fatty acid derivative and method for preparation thereof
RS63541B1 (sr) * 2015-12-31 2022-09-30 Hanmi Pharm Ind Co Ltd Trojni aktivator koji aktivira glukagonski, glp-1 i gip receptor

Also Published As

Publication number Publication date
HUE059737T2 (hu) 2022-12-28
JP2019504055A (ja) 2019-02-14
CA3010265C (en) 2025-05-20
CN109071624A (zh) 2018-12-21
EA201891359A1 (ru) 2019-01-31
DK3398961T3 (da) 2022-08-22
PH12018501411A1 (en) 2019-04-08
JP6712323B2 (ja) 2020-06-17
CO2018006986A2 (es) 2018-07-10
KR20190060749A (ko) 2019-06-03
CL2022000558A1 (es) 2022-09-23
PE20250556A1 (es) 2025-02-24
DOP2018000157A (es) 2018-10-15
BR112018013525A2 (pt) 2018-12-04
EP3398961B1 (en) 2022-06-29
IL260310B2 (en) 2024-02-01
US10400020B2 (en) 2019-09-03
CN115920077A (zh) 2023-04-07
CR20180381A (es) 2019-01-14
HK1258177A1 (en) 2019-11-08
CA3010182A1 (en) 2017-07-06
JP7526039B2 (ja) 2024-07-31
JP2019504057A (ja) 2019-02-14
CN115920077B (zh) 2025-07-04
KR20190105542A (ko) 2019-09-17
SA518391903B1 (ar) 2022-08-01
KR20190104958A (ko) 2019-09-11
AU2019203888B2 (en) 2021-05-13
PH12018501409A1 (en) 2019-04-08
JP7030894B2 (ja) 2022-03-07
IL260310B1 (en) 2023-10-01
WO2017116204A1 (ko) 2017-07-06
TW202216748A (zh) 2022-05-01
US10981967B2 (en) 2021-04-20
AU2019203891B2 (en) 2021-05-13
JP6712322B2 (ja) 2020-06-17
TWI731015B (zh) 2021-06-21
HK1255834A1 (en) 2019-08-30
JP2022130723A (ja) 2022-09-06
TWI807580B (zh) 2023-07-01
US20180311315A1 (en) 2018-11-01
TW201737945A (zh) 2017-11-01
US20190002520A1 (en) 2019-01-03
KR102285378B1 (ko) 2021-08-04
US20220213164A1 (en) 2022-07-07
CN108699125A (zh) 2018-10-23
KR20200095436A (ko) 2020-08-10
ZA201804998B (en) 2019-05-29
IL260318B2 (en) 2024-02-01
CO2018006982A2 (es) 2018-07-10
EA038544B1 (ru) 2021-09-13
JP2020171287A (ja) 2020-10-22
US20190153060A1 (en) 2019-05-23
EP3398961A4 (en) 2019-06-12
KR102179392B1 (ko) 2020-11-16
TW202330585A (zh) 2023-08-01
KR102401869B1 (ko) 2022-05-25
US20210188937A1 (en) 2021-06-24
PE20181494A1 (es) 2018-09-18
AU2016382394B2 (en) 2019-07-04
CL2022000557A1 (es) 2022-09-23
AU2016382393B2 (en) 2019-07-04
PH12018501409B1 (en) 2023-03-10
PH12018501411B1 (en) 2024-02-23
EA201891360A1 (ru) 2018-12-28
US20190218269A1 (en) 2019-07-18
TWI800478B (zh) 2023-05-01
EP3398962A1 (en) 2018-11-07
KR102285377B1 (ko) 2021-08-04
KR20200096184A (ko) 2020-08-11
JP2020128428A (ja) 2020-08-27
KR20170080521A (ko) 2017-07-10
ECSP18053053A (es) 2018-07-31
EP3398961A1 (en) 2018-11-07
SG11201805586SA (en) 2018-07-30
MX2018008027A (es) 2018-11-29
NZ744306A (en) 2024-05-31
CR20180380A (es) 2018-12-07
ECSP18053055A (es) 2018-07-31
CN108699125B (zh) 2022-10-28
KR102179391B1 (ko) 2020-11-16
CL2020002034A1 (es) 2020-10-09
SA518391891B1 (ar) 2021-07-12
NZ744321A (en) 2024-04-26
WO2017116205A1 (ko) 2017-07-06
AU2019203891A1 (en) 2019-06-20
ZA201804997B (en) 2019-05-29
SG11201805573RA (en) 2018-07-30
KR102367997B1 (ko) 2022-03-02
PL3398961T3 (pl) 2022-09-26
CN116059389A (zh) 2023-05-05
US11332508B2 (en) 2022-05-17
IL260318A (en) 2018-08-30
EA038524B1 (ru) 2021-09-09
IL260310A (en) 2018-08-30
RS63541B1 (sr) 2022-09-30
AU2019203888A1 (en) 2019-06-20
CL2018001795A1 (es) 2018-08-10
TW201730207A (zh) 2017-09-01
ES2925098T3 (es) 2022-10-13
CN116063454A (zh) 2023-05-05
HRP20220995T1 (hr) 2022-11-11
TN2018000228A1 (en) 2019-10-04
DOP2018000159A (es) 2018-09-30
IL260318B1 (en) 2023-10-01
KR20190062344A (ko) 2019-06-05
TWI877582B (zh) 2025-03-21
BR112018013530A2 (pt) 2018-12-04
TN2018000231A1 (en) 2019-10-04
US10370426B2 (en) 2019-08-06
MX2018008128A (es) 2018-12-06
KR20170080522A (ko) 2017-07-10
CL2020002033A1 (es) 2020-10-09
CN116063453A (zh) 2023-05-05
CA3010265A1 (en) 2017-07-06
EP3398962A4 (en) 2019-08-07
AU2016382393A1 (en) 2018-08-02
CN109071624B (zh) 2023-01-17
PT3398961T (pt) 2022-09-05
EP3985017A1 (en) 2022-04-20
AU2016382394A1 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
CL2018001776A1 (es) Agonista triple de receptores de glucagón/glp-1/gip
EP3359445A4 (en) GEOSTATIONARY HEIGHT PLATFORM
EA201791117A1 (ru) Частичные агонисты инсулинового рецептора
AR101896A1 (es) Uso de un agonista dual del receptor de glp-1 / glucagon de acción prolongada para el tratamiento de la enfermedad del hígado graso no alcohólico
CL2015002738A1 (es) Xantinas sustituidas y métodos de uso de las mismas.
ES2897914T8 (es) Compuestos que contienen nitrógeno, adecuados para el uso en la producción de poliuretanos
MX2020003217A (es) Coagonistas de accion prolongada de los receptores de glucagon y glp-1.
BR112016017402A2 (pt) fusões anti-pcsk9~glp-1 e métodos para uso
CL2018003045A1 (es) Semaglutida en afecciones cardiovasculares.
DK3347360T3 (da) Forbindelser, som er anvendelige til inhibering af ror-gamma-t
DOP2017000264A (es) Metodo para crear un compuesto a base de mercurio, compuesto a base de mercurio, metodos de uso del compuesto a base de mercurio y usos del compuesto a base de mercurio
ES1148633Y (es) Equipo autonomo para suministro de biomasa.
CL2018000420A1 (es) Nuevo derivado de catecol y composición farmacéutica que comprende el mismo.
BR112018067344A2 (pt) liraglutida em condições cardiovasculares
ITUA20161920A1 (it) Aeroplano per trasporti civili
CR20140051A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
MY199261A (en) Long-acting conjugate of triple glucagon/glp-1/gip receptor agonist
MX385250B (es) Jabones antimicrobianos que contienen carvacrol y metodos de uso de los mismos.
ES1149058Y (es) Arnés de seguridad para niños en sofás.